534 related articles for article (PubMed ID: 19873981)
1. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors.
Jones P; Altamura S; Boueres J; Ferrigno F; Fonsi M; Giomini C; Lamartina S; Monteagudo E; Ontoria JM; Orsale MV; Palumbi MC; Pesci S; Roscilli G; Scarpelli R; Schultz-Fademrecht C; Toniatti C; Rowley M
J Med Chem; 2009 Nov; 52(22):7170-85. PubMed ID: 19873981
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of substituted 2-phenyl-2H-indazole-7-carboxamides as potent poly(ADP-ribose) polymerase (PARP) inhibitors.
Scarpelli R; Boueres JK; Cerretani M; Ferrigno F; Ontoria JM; Rowley M; Schultz-Fademrecht C; Toniatti C; Jones P
Bioorg Med Chem Lett; 2010 Jan; 20(2):488-92. PubMed ID: 20007017
[TBL] [Abstract][Full Text] [Related]
3. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.
Menear KA; Adcock C; Boulter R; Cockcroft XL; Copsey L; Cranston A; Dillon KJ; Drzewiecki J; Garman S; Gomez S; Javaid H; Kerrigan F; Knights C; Lau A; Loh VM; Matthews IT; Moore S; O'Connor MJ; Smith GC; Martin NM
J Med Chem; 2008 Oct; 51(20):6581-91. PubMed ID: 18800822
[TBL] [Abstract][Full Text] [Related]
4. Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.
Jones P; Wilcoxen K; Rowley M; Toniatti C
J Med Chem; 2015 Apr; 58(8):3302-14. PubMed ID: 25761096
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of N-substituted indazole-3-carboxamides as poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors(†).
Patel MR; Pandya KG; Lau-Cam CA; Singh S; Pino MA; Billack B; Degenhardt K; Talele TT
Chem Biol Drug Des; 2012 Apr; 79(4):488-96. PubMed ID: 22177599
[TBL] [Abstract][Full Text] [Related]
6. Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors.
Eltze T; Boer R; Wagner T; Weinbrenner S; McDonald MC; Thiemermann C; Bürkle A; Klein T
Mol Pharmacol; 2008 Dec; 74(6):1587-98. PubMed ID: 18809672
[TBL] [Abstract][Full Text] [Related]
7. The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y; Calvert H
Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
[TBL] [Abstract][Full Text] [Related]
8. BRCA in breast cancer: from risk assessment to therapeutic prediction.
Diamond JR; Borges VF; Eckhardt SG; Jimeno A
Drug News Perspect; 2009 Dec; 22(10):603-8. PubMed ID: 20140280
[TBL] [Abstract][Full Text] [Related]
9. [PARP inhibitors: new therapeutic agents in breast and ovarian cancer].
Mercier-Vogel L; Bodmer A; Castiglione M
Rev Med Suisse; 2011 May; 7(296):1137-40. PubMed ID: 21721203
[TBL] [Abstract][Full Text] [Related]
10. Discovery and SAR of novel, potent and selective hexahydrobenzonaphthyridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).
Torrisi C; Bisbocci M; Ingenito R; Ontoria JM; Rowley M; Schultz-Fademrecht C; Toniatti C; Jones P
Bioorg Med Chem Lett; 2010 Jan; 20(2):448-52. PubMed ID: 20015648
[TBL] [Abstract][Full Text] [Related]
11. Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes.
Qian Y; Wertheimer SJ; Ahmad M; Cheung AW; Firooznia F; Hamilton MM; Hayden S; Li S; Marcopulos N; McDermott L; Tan J; Yun W; Guo L; Pamidimukkala A; Chen Y; Huang KS; Ramsey GB; Whittard T; Conde-Knape K; Taub R; Rondinone CM; Tilley J; Bolin D
J Med Chem; 2011 Apr; 54(7):2433-46. PubMed ID: 21413799
[TBL] [Abstract][Full Text] [Related]
12. Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.
Gandhi VB; Luo Y; Liu X; Shi Y; Klinghofer V; Johnson EF; Park C; Giranda VL; Penning TD; Zhu GD
Bioorg Med Chem Lett; 2010 Feb; 20(3):1023-6. PubMed ID: 20045315
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
Drew Y; Mulligan EA; Vong WT; Thomas HD; Kahn S; Kyle S; Mukhopadhyay A; Los G; Hostomsky Z; Plummer ER; Edmondson RJ; Curtin NJ
J Natl Cancer Inst; 2011 Feb; 103(4):334-46. PubMed ID: 21183737
[TBL] [Abstract][Full Text] [Related]
14. Identification of substituted pyrazolo[1,5-a]quinazolin-5(4H)-one as potent poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors.
Orvieto F; Branca D; Giomini C; Jones P; Koch U; Ontoria JM; Palumbi MC; Rowley M; Toniatti C; Muraglia E
Bioorg Med Chem Lett; 2009 Aug; 19(15):4196-200. PubMed ID: 19541484
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibitors in breast cancer.
Telli ML; Ford JM
Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
[TBL] [Abstract][Full Text] [Related]
16. Rational design of conformationally restricted quinazolinone inhibitors of poly(ADP-ribose)polymerase.
Hattori K; Kido Y; Yamamoto H; Ishida J; Iwashita A; Mihara K
Bioorg Med Chem Lett; 2007 Oct; 17(20):5577-81. PubMed ID: 17804225
[TBL] [Abstract][Full Text] [Related]
17. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent.
Wang B; Chu D; Feng Y; Shen Y; Aoyagi-Scharber M; Post LE
J Med Chem; 2016 Jan; 59(1):335-57. PubMed ID: 26652717
[TBL] [Abstract][Full Text] [Related]
18. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
Ratnam K; Low JA
Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
[TBL] [Abstract][Full Text] [Related]
19. Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy.
Hay T; Jenkins H; Sansom OJ; Martin NM; Smith GC; Clarke AR
Cancer Res; 2005 Nov; 65(22):10145-8. PubMed ID: 16287996
[TBL] [Abstract][Full Text] [Related]
20. Small-molecule PARP modulators--current status and future therapeutic potential.
Penning TD
Curr Opin Drug Discov Devel; 2010 Sep; 13(5):577-86. PubMed ID: 20812149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]